News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
720,445 Results
Type
Article (42578)
Company Profile (294)
Press Release (677573)
Multimedia
Podcasts (82)
Webinars (12)
Section
Business (210492)
Career Advice (2093)
Deals (36641)
Drug Delivery (107)
Drug Development (83071)
Employer Resources (176)
FDA (16590)
Job Trends (15420)
News (356140)
Policy (33935)
Tag
Academia (2599)
Accelerated approval (5)
Adcomms (22)
Allergies (92)
Alliances (51459)
ALS (100)
Alzheimer's disease (1409)
Antibody-drug conjugate (ADC) (141)
Approvals (16587)
Artificial intelligence (281)
Autoimmune disease (24)
Automation (17)
Bankruptcy (371)
Best Places to Work (11771)
BIOSECURE Act (20)
Biosimilars (112)
Biotechnology (188)
Bladder cancer (81)
Brain cancer (30)
Breast cancer (302)
Cancer (2396)
Cardiovascular disease (190)
Career advice (1754)
Career pathing (31)
CAR-T (164)
Cell therapy (457)
Cervical cancer (20)
Clinical research (67704)
Collaboration (892)
Company closure (2)
Compensation (583)
Complete response letters (25)
COVID-19 (2666)
CRISPR (49)
C-suite (262)
Cystic fibrosis (106)
Data (2407)
Decentralized trials (2)
Denatured (29)
Depression (47)
Diabetes (284)
Diagnostics (6473)
Digital health (20)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (119)
Drug shortages (28)
Duchenne muscular dystrophy (102)
Earnings (89010)
Editorial (41)
Employer branding (22)
Employer resources (150)
Events (115689)
Executive appointments (768)
FDA (18018)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (796)
Gene editing (119)
Generative AI (22)
Gene therapy (345)
GLP-1 (765)
Government (4558)
Grass and pollen (5)
Guidances (174)
Healthcare (19005)
Huntington's disease (25)
IgA nephropathy (29)
Immunology and inflammation (136)
Indications (31)
Infectious disease (2812)
Inflammatory bowel disease (147)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (101)
Interviews (323)
IPO (16811)
IRA (47)
Job creations (4061)
Job search strategy (1493)
Kidney cancer (10)
Labor market (43)
Layoffs (501)
Leadership (18)
Legal (8383)
Liver cancer (77)
Lung cancer (331)
Lymphoma (166)
Machine learning (9)
Management (59)
Manufacturing (347)
MASH (81)
Medical device (13475)
Medtech (13480)
Mergers & acquisitions (20413)
Metabolic disorders (746)
Multiple sclerosis (85)
NASH (17)
Neurodegenerative disease (104)
Neuropsychiatric disorders (30)
Neuroscience (2005)
NextGen: Class of 2025 (6639)
Non-profit (4530)
Now hiring (41)
Obesity (393)
Opinion (230)
Ovarian cancer (83)
Pain (103)
Pancreatic cancer (89)
Parkinson's disease (159)
Partnered (22)
Patents (256)
Patient recruitment (121)
Peanut (49)
People (59358)
Pharmaceutical (91)
Pharmacy benefit managers (22)
Phase I (21010)
Phase II (29799)
Phase III (22308)
Pipeline (1481)
Policy (163)
Postmarket research (2654)
Preclinical (8959)
Press Release (68)
Prostate cancer (109)
Psychedelics (31)
Radiopharmaceuticals (252)
Rare diseases (412)
Real estate (6259)
Recruiting (68)
Regulatory (23207)
Reports (50)
Research institute (2371)
Resumes & cover letters (358)
Rett syndrome (7)
RNA editing (8)
RSV (42)
Schizophrenia (80)
Series A (138)
Series B (93)
Service/supplier (12)
Sickle cell disease (57)
Special edition (17)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3730)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (57)
The Weekly (51)
Vaccines (722)
Venture capitalists (42)
Weight loss (257)
Women's health (36)
Worklife (16)
Date
Today (152)
Last 7 days (908)
Last 30 days (3544)
Last 365 days (32957)
2025 (12769)
2024 (35772)
2023 (40631)
2022 (51798)
2021 (56330)
2020 (54793)
2019 (47398)
2018 (35771)
2017 (33139)
2016 (32663)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (783)
Alabama (55)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (40795)
Australia (6537)
California (6630)
Canada (2123)
China (562)
Colorado (284)
Connecticut (287)
Delaware (164)
Europe (87203)
Florida (983)
Georgia (220)
Idaho (57)
Illinois (572)
India (26)
Indiana (333)
Iowa (11)
Japan (180)
Kansas (107)
Kentucky (24)
Louisiana (12)
Maine (63)
Maryland (943)
Massachusetts (4952)
Michigan (231)
Minnesota (411)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (70)
New Hampshire (63)
New Jersey (1846)
New Mexico (29)
New York (1859)
North Carolina (1027)
North Dakota (8)
Northern California (2917)
Ohio (213)
Oklahoma (14)
Oregon (39)
Pennsylvania (1464)
Puerto Rico (13)
Rhode Island (33)
South America (1165)
South Carolina (27)
South Dakota (1)
Southern California (2483)
Tennessee (108)
Texas (984)
United States (24817)
Utah (193)
Virginia (166)
Washington D.C. (65)
Washington State (586)
West Virginia (3)
Wisconsin (61)
720,445 Results for "biomarin pharmaceutical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Opinion
Competition for Achondroplasia Treatments Heats Up Slowly
Achondroplasia, which affects around one in 20,000 babies, has just one approved treatment: BioMarin’s Voxzogo. However, new investigational treatments are vying to compete in the area.
January 27, 2025
·
4 min read
·
Jia Jie Chen
Press Releases
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
May 16, 2025
·
18 min read
Mergers & acquisitions
BioMarin Expands Enzyme Expertise With $270M Inozyme Buy
The star of the acquisition is the enzyme replacement therapy INZ-701, being developed for the rare disease ENPP1 deficiency.
May 16, 2025
·
2 min read
·
Tristan Manalac
Press Releases
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
May 2, 2025
·
25 min read
Earnings
BioMarin Surpasses Analysts’ Q3 Sales Estimates Despite Voxzogo’s Slight Miss
The biotech beat Wall Street’s third-quarter revenue forecast by 6%, driven by increased uptake of its achondroplasia drug Voxzogo. However, William Blair downgraded BioMarin’s shares to market perform due to a “lack of near-term catalysts” and uncertainty around Voxzogo’s potential revenue growth.
October 30, 2024
·
2 min read
·
Tristan Manalac
Press Releases
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
May 12, 2025
·
14 min read
Press Releases
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
April 2, 2025
·
13 min read
Press Releases
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
February 24, 2025
·
3 min read
Podcast
BioMarin Fails to Reassure Investors, Terns Moves Forward in Obesity, ESMO Excitement
BioMarin’s new business strategy leaves investors with questions; Lykos CEO steps down; Terns releases compelling data on oral weight loss candidate; and more.
September 11, 2024
·
1 min read
·
Heather McKenzie
Press Releases
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
April 17, 2025
·
1 min read
1 of 72,045
Next
